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INTRODUCTION 
Breast cancer is the most common of all cancers and is the leading 
cause of cancer deaths in women worldwide, accounting for >1.6% of 
deaths and case fatality rates are highest in low-resource countries. A 
recent study of breast cancer risk in India revealed that 1 in 28 women 
develop breast cancer during her lifetime. This is higher in urban areas 
being 1 in 22 in a lifetime compared to rural areas where this risk is 
relatively much lower being 1 in 60 women developing breast cancer in 
their lifetime. In India the average age of the high risk group is 43-46 
years unlike in the west where women aged 53-57 years are more prone 
to breast cancer. 
The overall incidence of breast cancer has been rising because of 
increases in the average life span, lifestyle changes that increase risk for 
breast cancer, and improved survival from other diseases. Despite an 
increasing incidence, mortality from breast cancer has continued to fall, 
thought to be the result of both earlier detection via mammographic 
screening and improvements in therapy. Current treatment of breast 
cancer is guided by recent insights into breast cancer biology, an 
increasing ability to define disease biology and status in individual 
patients, and the availability of improved treatments.  
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            This is a prospective study conducted at RGGGH. All patients 
suspected to have breast cancer undergo detailed clinical examination. 
Routine investigations, FNAC/core-cut biopsy, Mammogram, USG 
abdomen, bone scan are taken to aid in the diagnosis. Staging of the 
malignancy in done according to the AJCC Classification. Tumors were 
subjected to Histopathological examination after surgery and ER and PR 
status checked. 
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AIMS  AND  OBJECTIVES 
COMPARISION OF CARCINOMA BREAST IN PRE-
MENOPAUSAL AND POST-MENOPAUSAL WOMEN 
1. To compare the clinical stage at presentation. 
2. To compare Body Mass Index [BMI]. 
3. To compare the incidence of various pathological types of 
carcinoma breast. 
4. To compare ER and PR status. 
5. To compare associated proliferative breast diseases. 
6. To compare incidence of mammographic abnormalities in 
contralateral breast. 
 
4
REVIEW OF LITERATURE 
BRIEF SURGICAL HISTORY OF BREAST : 
• In 1600 B.C. Ebers Papyrus (Egypt) suggested Heat cauterization 
and Excision of Breast tumors by knife. 
• In 525 B.C. Democedes successfully treated a woman with Breast 
tumor. 
• In 460 - 377 B.C. Hippocrates made detailed references to Breast 
cancer and its effects. 
• In 130 – 200 A.D. Galen claimed an excess of black bile 
(melancholia) caused cancer. Treatment centered on nutrition and 
purgation. Surgical excision was only recommended if tumor was 
removable. 
• In 1514-1564 Andreas Vesalius did wide excision and used 
ligatures for hemostasis. 
• In 1510-1590 Pare recognized relationship between breast cancer 
and axillary node involvement.  
• In 1786 Cruikshank  described lymphatic drainage of Breast. 
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• In 1845 Astley Cooper identified Suspensary ligaments of  Breast 
which were named after  him. 
• In 1867 Moore argued that local recurrence after Breast amputation 
was due to disseminated fragments not removed at the time of 
surgery. He suggested removal of  Breast along with surrounding  
tissue. 
• In 1870 Lister described antiseptic principles, supported and 
refined Moore's technique of axillary exposure and divided 
pectoral muscles. 
• In 1875 Volkmann proposed wide excision of Breast, skin and 
pectoral fascia. In advanced cases he removed pectoralis major 
muscle and sometimes pectoralis minor muscle. 
• In 1878 Billroth did Lumpectomy for early Breast cancer. 
• In 1882-1907 Halsted described Radical mastectomy. He did 
axillary clearance in all cases and also removed pectoralis major in 
most of them giving wide margin of clearance. 
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• In 1885 Sappey  noted the presence of subareolar plexus into which 
parenchymal lymphatics drained, claiming that most of drainage 
was to axilla. 
• In 1891 Welch used frozen sections in diagnosis of breast cancer. 
• In 1895 Czerny replaced surgically removed breast with large 
lipoma (breast reconstruction). 
• In 1896 Tansini performed immediate breast reconstruction using 
latissimus dorsi musculocutaneous flap after radical mastectomy. 
• In 1897 Gocht irradiated a case of inoperable breast cancer 
(Roentgen's x-rays were discovered in 1895). 
• In 1899 Rotter noted metastases while tracing lymphatics from 
breast to inter-pectoral nodes. 
• In 1918 Stibbe published detailed study on internal mammary 
lymphatics. 
• In 1927 W.S. Handley suggested standard radical mastectomy be 
extended to include internal mammary lymphatics. Also implanted 
radium tubes parasternally as prophylaxis. 
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• In 1938, Gershon-cohen recommended screening for breast cancer. 
• In 1943, Patey and Dyson developed modified radical mastectomy. 
Advocated wide skin excision and axilla clearing while sparing 
pectoralis major muscle. 
• In 1948 McWhirter promoted combination of simple mastectomy 
and high voltage x-ray therapy. 
• In 1960, Egan described modern mammography. 
• In 1963, Gros proposed "senology" as special discipline for study 
of breasts. 
• In 1963 Dodd et al. did First needle-localization procedure. 
Published in 1965.  
• In 1964, Witten stated that 80-90% of breast cancer determined by 
surgical biopsy can also be discovered from mammography. 
• In 1965, Auchincloss and Madden described radical mastectomy 
preserving both pectoralis major muscles. 
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• In 1971, Fischer and NSABP members initiated protocol B-04 
comparing radical mastectomy plus radiotherapy and total 
mastectomy alone. 
• In 1976, NSABP protocol B-06 was started. It compared total 
mastectomy, lumpectomy plus irradiation and lumpectomy alone. 
• In 1977, Dreaver pioneered breast reconstruction with 
myocutaneous flaps. Published in major journals in 1981, 1986. 
• In 1978, Bostwick described and popularised  use of latissimus 
dorsi myocutaneous flap. 
• In 1981, Turner and  Maddox reported on the Manchester and 
University of Alabama trials of radical versus modified radical 
mastectomy, finding no difference in survival. 
• In 1992-1994 Krag and Guiliano published development of 
sentinel lymph node mapping for carcinoma Breast. 
• In 1995, genetic mutations causing breast carcinoma were 
identified, named as BRCA-1 and BRCA-2 by researchers. 
• In 1997, March et al. Joint Task Force conducted  National surveys 
of breast core biopsy use. 
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• In 2007, Bevacizumab, monoclonal antibody directed against 
VEGF was introduced as adjuvant treatment for carcinoma breast. 
EPIDEMIOLOGY OF BREAST CANCER :  
• Breast cancer is the most common neoplasm in women, accounting 
for 26% of cancers diagnosed annually. 
• It is overall the second leading cause of deaths due to cancer 
following lung cancer, and in women >65 years it is the leading 
cause of death. 
• The incidence of breast cancer is highest among women of higher 
socio economic background. 
• Over the last 10 years mortality due to breast cancer has been 
steadily decreasing most likely due to early detection and improved 
efficacy of adjuvant therapies. 
• The lifetime risk of an Indian woman developing breast cancer is 1 
in 28. It is higher in urban women as compared to rural women. 
• The incidence of breast cancer in Indian population as per 2006 is 
20.01 per 1,00,000 population and mortality is 4.32 per  1,00,000 
population. 
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EMBRYOLOGY : 
LINE OF SCHULTZ 
 
• The breast is a group of large glands derived from the epidermis. 
• During the second month of gestation, two bands of slightly 
thickened ectoderm appear on the ventral body wall extending 
from above the axilla to below the groin. 
• In humans, only the pectoral portion of these bands will persist and 
ultimately develop into adult mammary glands. 
• The glandular portion of the breast develops from the ectoderm. It 
arises from the local thickening of the epidermis. From this 
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thickening, 16 to 24 buds of ectodermal cells grow into the 
underlying mesoderm (dermis) during the twelfth week. These 
buds, at first solid, will become canalized near term to form the 
lactiferous ducts 
• The connective-tissue stroma of the breast forms from the 
mesoderm, which will form the dermis of the skin and the 
superficial fascia (tela subcutanea) as well. Fibers forming the 
suspensory ligaments (of Cooper) will develop from both layers. 
This development, as well as the appearance of fat in the 
superficial fascia, does not occur until puberty in the female 
ANATOMY OF BREAST: 
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• The breast lies in the subcutaneous plane over the pectoral region, 
base extending from midline to anterior or midaxillary line and 2nd 
to 6th ribs, nipple approximately situated at the level of 4th 
intercostal space. 
• It overlies the pectoralis major, serratus anterior and to some extent 
the rectus sheath and external oblique muscle 
• The breast is separated from the underlying muscles by a 
condensation of superficial fascia, called pectoral fascia. 
• A small extension into the upper quadrant reaching the medial wall 
of axilla is known as the Axillary tail of Spence, which is often 
poorly connected with the ductal system. 
• Its clinical significance lies in that the swellings arising from this 
tail, may be readily mistaken for lymph nodes. 
• The axillary tail of Spence enters the axilla through an opening in 
the pectoral fascia known as the foramen of Langer, at the level of 
the 3rd intercostal space. 
• About 20 lactiferous ducts converge radially to open on the nipple, 
a cylindrical projection on the summit of the breast. 
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• The nipple is surrounded by circular pigmented skin called as the 
Areola. 
• Sebaceous glands under the areola form small elevations, known as 
Montgomery’s tubercles. 
• Fibrous septa running between the skin and pectoral fascia called 
as the Suspensory ligaments of Cooper, through the mammary 
tissue help to maintain their shape in young breasts and their atropy 
in elderly account for the sagging of their breasts. 
• These septa also explain skin tethering in early malignancy and 
orange peel appearance in diseases that produce cutaneous 
lymphedema. 
ANATOMY OF AXILLA : 
• It is a pyramidal space wedged between the upper arm and the side 
of the chest and ceases to exist when the arm is hyperabducted. 
• It is limited by anterior and posterior folds, communicating above 
with the supra clavicular fossa, through the apex which transmits 
the neurovascular and lymphatic structures. 
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• The anterior wall is formed by pectoralis major, minor, subclavius 
and clavipectoral fascia. 
• The posterior wall extends lower and is formed by subscapularis, 
teres major and latissimus dorsi. 
• The lateral wall is the narrowest, since the anterior and posterior 
walls converge to the lips of the bicipital groove, this is formed by 
the upper humerus, coraco-brachialis, biceps muscles and the 
axillary neurovascular structures. 
• Medially it is bounded by the upper five ribs, the intercostals and 
upper digitations of serratus anterior muscle. 
• The floor is formed by the axillary fascia, bridging from fascia 
over the serratus anterior to the deep fascia of the arm. 
• The action of pectolralis major is adduction and internal rotation of 
the shoulder, the former is employed to put the muscle into 
contraction, to detect fixity of a breast mass. 
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NORMAL DEVELOPMANT AND PHYSIOLOGY : 
• The breast development begins between the ages of 9 and 12. The 
events are initiated by low amplitude pulses of pituitary 
gonadotropins, which raise serum oestradiol concentration. 
• In breast this hormone dependent maturation entiles increased 
deposition of fat, the formation of new ducts by branching and 
elongation and the appearance of lobular units. 
• This process is controlled by pituitary hormones, progesterone, 
oestrogen, adrenal hormones and effects of thyoid hormones and 
insulin. 
• The mature post pubertal breast contains stroma, lobular units, 
lactiferous ducts and fat. During phases of menstrual cycle or in 
response to exogenous hormones, the breast stoma and epithelium 
of lobules undergo cyclic stimulation. The main process is not 
hyperplasia but alteration of morphology and hypertrophy, In late 
luteal phase there is fluid accumulation and intralobular oedema 
which are reasons for breast engorgement and pain 
• Although minor changes occur during each menstrual cycle, 
pregnancy and lactation bring about the ultimate development of 
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the breasts. Progesterone, prolactin, and placental lactogen are key 
hormones in stimulating the formation of secretory alveoli which 
develop at the ends of the branched ducts. As development 
continues, the cells of the secretory alveoli acquire increased 
organelles related to protein synthesis and secretion. 
• During lactation, prolactin from the anterior pituitary gland causes 
mammary glands to secrete milk proteins and lipids. Milk ejection 
occurs in response to the neural impulses elicited by sucking 
activity at the breast. This stimulus causes release of oxytocin by 
the paraventricular nuclei of the hypothalamus via the posterior 
pituitary gland. These neural impulses also inhibit the release of 
luteinizing hormone.  
• When nursing ceases, prolactin secretion is reduced. Nonejected 
milk in the alveoli effects the cessation of milk production. The 
alveoli regress, and the duct system regresses to the nonpregnant 
state.  
BLOOD SUPPLY : 
• The lateral thoracic artery from the 2nd part of axillary artery 
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• The perforating cutaneous branches of internal mammary artery to 
the 2nd, 3rd, and 4th intercostal spaces. 
• The lateral branches of the 2nd, 3rd and 4th intercostal arteries. 
• Pectoral branches of acromio-thoracic artery. 
VENOUS DRAINAGE : 
• The superficial veins from the breast characterised by their 
proximity to the skin drain to the axillary, internal mammary and 
intercostal vessels. 
• Through posterior intercostal veins, venous drainage communicates 
with the paravertebral venous plexus. So secondaries in vertebrae 
are common in carcinoma of the breast. 
LYMPHATIC DRAINAGE : 
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• Level 1 – Lymph nodes lateral to pectoralis minor muscle. 
• Level 2 – Lymph nodes deep to pectoralis minor muscle. 
• Level 3 – Lymph nodes medial to pectoralis minor muscle. 
• Lymphatic drainage of breast is of great clinical significance, outer 
quadrants predominantly draining into axillary and inner quadrants 
into internal mammary group of nodes on the same side. 
• However when these channels are blocked, alternate drainage 
pathway may take place, into supraclavicular nodes, opposite 
breast and axilla, peritoneal cavity and liver via rectus sheath  and 
falciform ligament. 
• The lymphatics of nipple and areola drains into subareolar  plexus 
of  Sappey, before they reach the regional nodes. 
The Axillary lymph nodes numbering around 50 are grouped as follows 
Anterior or Pectoral group,  
• Located under the anterior axillary fold 
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Posterior or Subscapular Group, 
• Located in the posteromedial wall of axilla, in relation to the 
posterior fold 
Lateral group, 
• Along the axillary vessels 
Apical group, 
• Which form the junction between the axillary and supraclavicular 
chains,  
Deltopectoral group, 
• Located above / medial to the pectoralis minor, in relation to the 
clavipectoral fascia. 
Interpectoral group, 
• Located between pectoralis minor and major muscles 
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ANOMALIES OF BREAST : 
One or both breasts may be hypoplastic due to under development 
of the lactiferous apparatus or grossly hypertrophied and pendulous 
(gigantomastia). 
Amastia – absence of breast, may be seen in Turner syndrome and 
congenital adrenal hyperplasia or tumors. Absence of a breast, sterno-
costal head of pectoralis major muscle, syndactylism and nephropathy is 
known as Poland syndrome. 
Athelia – absence of nipple. 
Polymastia or polythelia – supernumerary breasts or nipples 
might develop along the milk line, most often in the inframammary 
regions, due to incomplete involution of the mammary ridge (milk line) 
ABERRATIONS OF NORMAL DEVELOPMENT AND 
INVOLUTION (ANDI)  : 
It occurs due to a disturbance in the cyclical hyperplasia or 
involution changes that occur in the breast, often bilateral. 
It is seen in the 3rd and 4th decades of life and is common in 
spinster, nullipara and those who have not breast fed their children. 
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The pre-menstrual accentuation of subjective or objective features 
favour a hormonal hypothesis, supported by the relief of symptoms by 
cyclical hormonal treatment, however their precise role is ill understood. 
Its pathogenesis is not clear and wide range of processes occur 
such as fibrosis, adenosis, epitheliosis, cystic changes and inflammation, 
in varying proportions and combinations. 
The process starts with periductal fibrosis, probably secondary to 
oestrogen stimulation, which causes irritation of the cells lining the ducts 
and increased epithelial proliferation (epitheliosis) 
Progressive epithelial clumping gives a gland like appearance 
(adenosis) and obstruction to the ductal drainage causes the cystic 
changes 
The pre-malignant potential of  fibroadenosis is debatable and the 
higher incidence of malignancy seen in this disease may be related to 
continued oestrogen influence, which is a common denominator to both 
the conditions. 
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EARLY REPRODUCTIVE YEARS (AGE 15–25)  
NORMAL 
* Lobular development  
* Stromal development  
* Nipple eversion  
DISORDER 
* Fibroadenoma 
* Adolescent hypertrophy  
* Nipple inversion  
DISEASE  
* Giant fibroadenoma 
* Gigantomastia 
* Subareolar abscess 
LATER REPRODUCTIVE YEARS (AGE 25–40)   
NORMAL 
* Cyclical changes of menstruation  
* Nodularity 
* Epithelial hyperplasia of pregnancy  
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DISORDER 
* Cyclical mastalgia 
* Bloody nipple discharge 
DISEASE 
* Incapacitating mastalgia 
INVOLUTION (AGE 35-55) 
NORMAL 
* Involution of lobules 
* Involution of ducts 
* Epithelial turnover 
DISORDER 
* Duct ectasia 
* Nipple retraction 
* Epithelial hyperplasia 
DISEASE  
* Periductal mastitis 
* Epithelial hyperplasia with atypia 
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RELATIVE RISK FOR THE DEVELOPMENT OF BREAST 
CANCER IN ANDI 
Non proliferative :  No Increased Risk 
* Microcysts / macrocysts 
* Ectasia of ducts 
* Simple fibroadenoma 
* Mastitis 
* Fibrosis 
* Apocrine metaplasia or squamous metaplasia 
* Mild hyperplasia 
PROLIFERATIVE : RR 1.5 TO 2.0 
* Complex fibroadenoma 
* Papilloma 
* Sclerosing adenosis 
* Hyperplasia; moderate or severe 
PROLIFERATIVE WITH ATYPIA: RR 4.5 TO 5.0 
* Atypical ductal hyperplasia 
* Atypical lobular hyperplasia 
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RISK FACTORS  FOR DEVELOPMENT OF BREAST CANCER: 
RELATIVE RISK < 2 
* Early menarche 
* Late menopause 
* Nulliparity 
* Estrogen plus progesterone 
* Hormone replacement therapy 
* Alcohol use  
* Post-menopausal obesity 
RELATIVE RISK 2 TO 4 
* One first degree relative with breast cancer 
* CHEK 2 mutation 
* Age > 35 years at first child birth 
* Proliferative breast disease 
* Mammographic breast density 
RELATIVE RISK >4 
* Mutation - BRCA-1 or BRCA-2 
* LCIS 
* Atypical hyperplasia 
* Radiation exposure before 40 
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PATHLOGY OF BREAST CANCER : 
Invasive breast cancers constitute a heterogeneous group of lesions 
that differ with regard to their clinical presentation, radiographic 
characteristics, pathologic features, and biologic behavior. This 
classification scheme is based on the growth pattern and cytologic 
features of the invasive tumor cells 
CLASSIFICATION OF BREAST CARCINOMAS : 
NON-INVASIVE EPITHELIAL CARCINOMAS : 
Lobular carcinoma in situ 
Ductal carcinoma in situ, or intraductal carcinoma (papillary, 
cribriform, solid and comedo types) 
INVASIVE EPITHELIAL CARCINOMAS : 
DUCTAL 
Invasive, NOS (Not Otherwise Specified) 
Invasive with predominant intraductal component 
Intraductal (in situ) 
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Comedo 
Inflammatory 
Medullary with lymphocytic infiltrate 
Mucinous (colloid) 
Papillary 
Scirrhous 
Tubular 
Other 
LOBULAR 
In situ 
Invasive with predominant in situ component 
Invasive 
NIPPLE 
Paget's disease, NOS 
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Paget's disease with intraductal carcinoma 
Paget's disease with invasive ductal carcinoma 
OTHER 
Undifferentiated carcinoma 
The following are tumor subtypes that occur in the breast, but are not 
considered to be typical breast cancers: 
Cystosarcoma phyllodes 
Angiosarcoma 
Primary lymphoma 
DUCTAL CARCINOMA IN SITU : 
Broder’s definition of  DCIS still holds good, as the transformation 
of epithelial cells of any duct in the body into malignant cells, which 
however remain in the same normal anatomic position without having 
breached the basement membrane. 
In the pre mammography era, DCIS was rarely diagnosed 
clinically. It presented as discharge from the nipple or in later stages as 
the Paget’s disease of the nipple, with a palpable mass. 
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But with the advent of mammography, there has been a big surge 
in the detection of  DCIS, it is however not logical to adopt the same 
course of treatment to symptomatic and asymptomatic 
(mammographically  detected) DCIS. 
The commonest mammographic findings are calcifications (which 
originate from intraductal debris), necrotic tumor cells in the ductal 
epithelium and other tumor cell secretions. 10% may present as soft tissue 
abnormalies as in invasive carcinomas. 
The degree of cellular atypia and the presence of necrosis are the 
main features that delineate the grades of malignancy. 
For example a high grade lesion like comedo DCIS displays both 
atypia and necrosis. It is the necrotic debris within the ductal lumen that 
gives the appearance of comedone ( black head ). 
The low and intermediate grades of  DCIS such as the cribriform, 
micropapillary, papillary and circinate patterns, are associated with 
atypical cytology without necrosis. 
Multiple areas of rounded spaces within a stratified ductal 
epithelium characterise the cribriform pattern, giving the appearance of a 
sieve. 
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In papillary type the duct is filled with complex papillary folds. 
This has to be distinguished from a benign papilloma. 
The treatment of  DCIS is controversial. 
LOBULAR CARCINOMA IN SITU : 
This has no characteristic clinical feature and is sometimes found 
incidentally in mastectomy specimens. 
Its main properties are its high bilaterality (40%) and 
multicentricity (70%) and high risk (10 times greater than controls) of the 
subsequent development of  invasive carcinoma in one or both breasts. 
The duration required for the development of  invasive carcinoma 
from LCIS may be greater than 10 years, but these lesions require close 
monitoring by half yearly clinical examination and annual 
mammography. 
The advent of mammography has made the surveillance of these 
patients more comfortable and reassuring, but it is important that they are 
enlisted for a lifetime screening program, because with the passage of 
time the anxiety becomes less, but unfortunately the risks become more. 
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INVASIVE CARCINOMA : 
When stromal invasion is detectable, the tumors come under this 
category. 
By far the commonest variety is the invasive ductal carcinoma of 
non specific type referred to as the NOS ( Not Otherwise Specified ). 
This forms >80% of all carcinomas of breast in which no specific 
pattern is detectable. 
All the special subtypes form the remaining such as tubular, 
mucinous, medullary and invasive lobular which tend to be better 
differentiated and have better prognosis than the NOS. 
This implies that most ductal carcinomas are undifferentiated and 
cannot be easily classified morphologically. 
The tumor cells may be in groups, cords or glands. The amount of 
stroma ranges from none to abundant and its appearance from cellular to 
densely fibrous. 
In some of the cases of abundant stroma, it may be difficult to 
identify the tumor ( earlier called as the atropic scirrhous type) 
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The Bloom and Richardson grading to determine the degree of 
aggressiveness of tumor is based on 
* The tendency of cells to form tubules 
* The pleomorphism of the nucleoli 
* Frequency of hyper chromatic nuclei 
Other histologic types of  invasive carcinoma, 
Tubular carcinoma representing about 3-5 % of the invasive 
carcinoma shows the tumor cells differentiated into tubular pattern. In its 
pure form it rarely metastasises. No further therapy is required if these 
tumors are excised with a 2 cm of normal tissue in all the dimensions. 
Cribriform carcinoma is another tumor which behaves 
biologically similar to tubular carcinoma. 
Mucinous colloid carcinoma, in which pools of extracellular 
mucin are found in with an embedded aggregate of tumor cells. This 
comprises 2-4% of invasive carcinoma, usually presents in older women 
and carries an excellent prognosis. 
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Medullary carcinoma has solid sheets of large cells, associated 
with lymphocytic reaction. 
Lobular carcinoma tends to be multifocal and also bilateral. 
Inflammatory carcinoma has previously been ascribed to tumours 
occurring in pregnancy and during lactation (mastitis carcinomatosis), 
although it is now apparent that it occurs in all age groups. This type of 
breast cancer has previously been diagnosed on the pathological 
observation of tumour emboli in dermal lymphatics, although it is now 
defined by its clinical appearance with more than 50 per cent of the breast 
being red and warm in association with a brief history. This condition is 
associated with a poor prognosis, whether or not the dermal lymphatics 
contain tumour. Some studies have indicated an improved survival, 
however, if dermal lymphatics contain tumour (‘pathologically defined 
inflammatory breast cancer') but the clinical picture is absent. 
Paget’s disease of the nipple, this type of breast carcinoma 
presents as a chronic eczema like lesion of the nipple / areola with nipple 
discharge. Upto 50% of patients have a palpable breast lump. It is seen in 
association with non invasive ductal carcinoma, which in due course 
turns invasive and may be limited to the ducts just beneath the nipple or 
sometimes beyond. Microscopically it is characterised by the presence of 
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large, ovoid cells with abundant clear pale staining cytoplasm in the 
Malpighian layer of epidermis. If eczema is not responding to 
conventional therapy within few weeks, skin biopsy must be done, as the 
prognosis is excellent, if treated before the mass is clinically felt, by wide 
local excision or mastectomy. With palpable mass it is treated as per the 
guidelines for other malignancies of  breast.  
CUTANEOUS MANIFESTATIONS OF CARCINOMA BREAST : 
Peau d’ orange  
Due to obstruction in the dermal lymphatics, openings of 
sebaceous glands and hair follicles get buried in the oedema giving rise to 
the orange peel appearance. 
Dimpling of skin 
Due to infiltration of ligament of cooper 
Retraction of nipple- 
Due to infiltration of lactiferous duct 
Ulceration and discharge from nipple or areola 
Skin ulceration and fungation 
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Cancer en cuirasse 
Skin over the chest wall and breast is studded with cancer nodule 
appearing like an armour coat. 
Tethering to skin 
SPREAD INTO DEEPER PLANE : 
Into pectoralis major muscle is confirmed by observing the 
restricted mobility of the swelling while contracting the muscle. 
Into latissimus dorsi muscle is confirmed by extending the shoulder 
against resistance. 
Into serratus anterior muscle is confirmed by pushing the wall with 
hands without flexing the elbow. 
Into the chest wall is confirmed that the breast will not fall forward 
while leaning forward and raising the arm above the shoulder, breast will 
not move upwards as it is fixed to the chest wall. 
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LYMPHATIC SPREAD : 
 
Occurs through 
* Subareolar sappey’s lymphatic plexus 
* Cutaneous lymphatics 
* Intramammary lymphatics 
Lymphatic spread almost always first occurs to the axillary lymph 
nodes. 
From the axillary lymph nodes spread occurs to the supraclavicular 
lymph nodes by lymphatic embolization. 
Through the dermal lymphatics it may spread to the contralateral 
breast or axilla. 
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* Spread restricted to level 1 nodes carries a better prognosis 
* Spread to level 2 has poor prognosis. 
* Spread to level 3 has the worst prognosis 
Spread may occur to the internal mammary lymph nodes of the 
same side and then to the mediastinal lymph nodes. 
Contralateral internal mammary nodes may also get involved by 
retrograde spread. 
Fixed enlarged axillary nodes may cause lymphedema due to 
lymphatic block, venous thrombosis and venous oedema due to venous 
block and severe excruciating pain along the distribution of the median 
and ulnar nerves with often significant sensory and motor deficits due to 
tumor infiltration of the cords of brachial plexus. 
HEMATOGENOUS SPREAD : 
Bone   
Commonest (70%), lumbar vertebrae, femur, ends of  long bones, 
thoracic vertebrae, ribs, skull in order. They are osteolytic lesions often 
with pathological fractures. Present with painful, tender, hard, non-mobile 
swelling with disability. Spine secondaries can cause paraplegia. 
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Liver 
Either through blood occasionally through trans coelomic spread. 
Lung 
Causes malignant pleural effusion and cannon ball secondaries. 
Brain 
Causes increased intracranial pressure, coning. 
Adrenals and ovaries. 
GENETICS OF CARCINOMA BREAST : 
 
About 5% of breast cancers are genetic, mutation of an autosomal 
dominant gene seems to account for the development of cancer. 
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The BRCA-1 found in the long arm of chromosome -17 is 
implicated in some breast cancers and has been recently cloned. 
Some mutations in this gene cause it to lose its function of 
suppression of cell division. 
BRCA-1 is also associated with 10-15%  lifetime risk of ovarian 
cancer. 
Another breast cancer gene BRCA-2 has been identified on the 
long arm of chromosome-13 and is also associated with increasd risk of 
developing breast and ovarian malignancies. 
In inherited breast cancers other genetic defects have also been 
established, e.g. mutation or loss of  heterozygosity of tumor suppressor 
gene p53 on the short arm of chromosome 17.  This occurs in  Li-
Fraumeni syndrome in which there is increased tendency to develop soft 
tissue sarcoma, breast cancer, melanoma etc. when associated with 
ovarian and colonic cancers it is known as Lynch type 2 syndrome. 
Those with Ataxia Telangiectasia syndrome also have increased 
risk of developing breast carcinoma, as also in Cowden’s disease 
(multiple hamartoma syndrome) due to defective tumor suppressor gene. 
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Patients carrying a genetically high risk require a close surveillance 
i.e. physical examination every six months and mammography annually. 
The situation is further complicated by the data that exposure to 
radiation during mammography, may increase the oncogenic risk in 
mutation carriers. 
Prophylactic bilateral mastectomy, recommended by some in such 
circumstances appear too aggressive and lacks universal approval at 
present time  
DIAGNOSTIC FACTORS IN BREAST CARCINOMA: 
MAMMOGRAPHY : 
Mammography showing invasive breast cancer 
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It is a plain x ray of soft tissue of breast using a low voltage and 
high amperage x rays 
Two films are taken 
Craniocaudal from above downward 
Mediolateral from side to side 
Dose of radiation is 0.1Gy, so it is a safe and effective procedure. 
Findings : 
Microcalcifications signify malignancy 
Soft tissue shadows may be smooth and regular in benign 
conditions and irregular in carcinomas 
Size and location of mass lesions 
Spiculations, duct distortion. 
BIRADS GRADING IN MAMMOGRAPHY: 
Grade 1 – Negative 
Grade 2 – Benign lesion 
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Grade 3 – Probably benign lesion 
Grade 4 – Suspicious of breast carcinoma 
Grade 5 – Highly suggestive of carcinoma 
Grade 6 – known carcinoma 
INDICATIONS : 
For screening purposes it is done after 40 years. Early screening is 
indicated when there is family history of carcinoma breast or histological 
risk factor. Mammography before 35 years is usually not done unless 
there is suspicious lump or a strong family history. 
* In obese patients 
* Whenever conservative breast surgeries are planned. 
* To find out spread or de novo tumor in the contralateral 
breast. 
* Mammography guided biopsy can be done. 
* Evaluation and follow up in benign breast disease with 
malignant potential. 
* Follow up mammography after conservative breast surgery. 
* Mastalgias. 
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Digital mammography is computerised electronic image of the 
breast with enhanced and magnified pictures. 
Digital spot view mammography allows faster and more accurate 
streotactic biopsy. 
Mammography fails to detect 10% to 15% of all palpable 
malignant lesions, and its sensitivity is particularly decreased in women 
with lobular carcinoma or radiographically dense breast tissue.  
Therefore, a negative mammogram should not influence the 
decision to perform a biopsy of a clinically palpable lesion. 
Xeromammography is the same as above but here a photo 
conductor is used to produce the final image on a selenium paper rather 
than on a x ray film. 
Advantages 
Edge enhancement effect, therefore useful in dense breasts. 
Disadvantages 
Exposure to high radiation dose and selenium plates are needed. 
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ULTRASOUND BREAST : 
The main value of ultrasonography is in distinguishing cystic from 
solid lesions.  
If the lesion is not palpable, ultrasonography can determine 
whether the lesion is cystic and thus potentially eliminate the need for 
additional workup or treatment. 
Ultrasonography has not proved useful for screening: it fails to 
detect calcifications, misses a large number of malignancies, and 
identifies a great deal of normal breast texture as potential nodules. 
It is useful, however, for directing fine-needle or core-needle 
biopsy of the lesions that it does visualize: it permits real-time 
manipulation of the needle and direct confirmation of the position of the 
needle within the lesion. 
MAGNETIC RESONANCE IMAGING : 
Magnetic resonance imaging after injection of gadolinium contrast 
enhances many malignant lesions in relation to normal breast 
parenchyma. 
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To differentiate scar from recurrence 
To image breasts of women with implants 
To evaluate the management of axilla  
To evaluate the management of recurrent disease 
It is also useful in screening of women in high risk group 
Irregular mass with spiculations, changes in skin and nipple, 
lymphedema are the findings in carcinoma breast. 
MRI breast is not accurate if done within 9 months of radiotherapy  
BIOPSY METHODS : 
Fine needle aspiration cytology 
Advantages : 
Simple office procedure 
Economical 
Less time consuming 
No scar 
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Does not interfere with further treatment 
Limitations : 
Errors in sampling, handling, processing and reading 
Does not show the architecture 
Not a substitute for excision biopsy 
Markers (ER and PR) not routinely available 
Requires experienced cytopathologist 
Core cutting needle biopsy : 
  Advantages : 
Rapid, relatively painless, inexpensive.  
No incision. 
Produces histological rather than a cytological 
diagnosis. 
Can be read by any pathologist, markers routinely 
available. 
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Disadvantages : 
False-negative results, 
Incomplete lesion characterization can occur. 
Difference between FNAC and core cut biopsy samples : 
 
Excisional biopsy : 
 Advantages : 
False-negative results rare.  
Complete histology before treatment decisions.  
May serve as definitive lumpectomy. 
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Disadvanges : 
Expensive, more painful. 
Creates an incision to be incorporated into definitive surgery. 
Unnecessary surgery with potential for cosmetic deformity 
in patients with benign abnormalities. 
TRIPLE ASSESSMENT : 
1. History and clinical examination 
2. Imaging – for patients below 40 years an ultrasound is 
performed, for those above 40 years mammogram is done. 
3. Fine needle aspiration cytology or Core cutting needle 
biopsy. 
METASTATIC WORK UP : 
An ultrasound abdomen is done to pick up liver metastasis, 
krukenberg tumor and ascites. 
An X-ray chest is done to see for pleural effusion, mediastinal 
widening and cannon ball secondary. 
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A bone scan for all patients with stage 3 disease, pathological 
fracture and elevated alkaline phosphatase. 
STAGING OF BREAST CARCINOMA : 
TNM STAGING : 
PRIMARY TUMOR (T) 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary  
Tis: Intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of 
the nipple    
Tis (DCIS): Ductal carcinoma in situ 
Tis (LCIS): Lobular carcinoma in situ 
Tis (Paget's): Paget's disease of the nipple with no tumor 
T1: Tumor not > 2.0 cm in greatest dimension 
T1mic: Microinvasion not >0.1 cm in greatest dimension 
T1a: Tumor > 0.1 cm but not >0.5 cm in greatest dimension 
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T1b: Tumor > 0.5 cm but not > 1.0 cm in greatest dimension 
T1c: Tumor > 1.0 cm but not > 2.0 cm in greatest dimension 
T2: Tumor > 2.0 cm but not > 5.0 cm in greatest dimension 
T3: Tumor > 5.0 cm in greatest dimension 
T4: Tumor of any size with direct extension to (a) chest wall or (b) skin,   
T4a: Extension to chest wall, not including pectoralis muscle 
T4b: Edema (including peau d'orange) or ulceration of the skin of 
the breast, or satellite skin nodules confined to the same breast 
T4c: Both T4a and T4b 
T4d: Inflammatory carcinoma 
REGIONAL LYMPH NODES (N) 
NX: Lymph nodes cannot be assessed (e.g., previously removed) 
N0: No regional lymph node metastasis 
N1: Metastasis to movable ipsilateral axillary lymph node(s) 
 
51
N2: Metastasis to ipsilateral axillary lymph node(s) fixed or matted, or in 
clinically apparent  ipsilateral internal mammary nodes in the absence of 
clinically evident axillary nodal metastasis 
N2a: Metastasis in ipsilateral axillary lymph nodes fixed to one 
another (matted) or to other structures 
N2b: Metastasis only in clinically apparent  ipsilateral internal 
mammary nodes and in the absence of clinically evident axillary 
lymph node metastasis 
N3: Metastasis in ipsilateral infraclavicular lymph node(s) with or 
without axillary lymph node involvement, or in clinically apparent 
ipsilateral internal mammary lymph node(s) and in the presence of 
clinically evident axillary lymph node metastasis; or, metastasis in 
ipsilateral supraclavicular lymph node(s) with or without axillary or 
internal mammary lymph node involvement 
N3a: Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b: Metastasis in ipsilateral internal mammary lymph node(s) and 
axillary lymph node(s) 
N3c: Metastasis in ipsilateral supraclavicular lymph node(s) 
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PATHOLOGIC CLASSIFICATION (pN) 
pNX: Regional lymph nodes cannot be assessed (e.g., not removed for 
pathologic study or previously removed) 
pN0: No regional lymph node metastasis histologically, and no additional 
examination for isolated tumor cells (ITC) 
[Note: ITCs are defined as single tumor cells or small cell clusters not 
larger than 0.2 mm, usually detected only by immunohistochemical (IHC) 
or molecular methods but that may be verified on hematoloxylin and 
eosin (H&E) stains. ITCs do not usually show evidence of malignant 
activity, e.g., proliferation or stromal reaction]. 
pN0(I-): No regional lymph node metastasis histologically, 
negative IHC 
pN0(I+): No regional lymph node metastasis histologically, 
positive IHC, and no IHC cluster larger than 0.2 mm 
pN0(mol-): No regional lymph node metastasis histologically, and 
negative molecular findings (RT-PCR) 
pN0(mol+): No regionally lymph node metastasis histologically, 
and positive molecular findings (RT-PCR) 
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pN1: Metastasis in one to three axillary lymph nodes, and/or in internal 
mammary nodes with microscopic disease detected by SLN dissection 
but not clinically apparent 
pN1mi: Micrometastasis (larger than 0.2 mm but not larger than 
2.0 mm) 
pN1a: Metastasis in one to three axillary lymph nodes 
pN1b: Metastasis in internal mammary nodes with microscopic 
disease detected by SLN dissection but not clinically apparent 
pN1c: Metastasis in one to three axillary lymph nodes and in 
internal mammary lymph nodes with microscopic disease detected 
by SLN dissection but not clinically apparent. (If associated with 
more than three positive axillary lymph nodes, the internal 
mammary nodes are classified as pN3b to reflect increased tumor 
burden.) 
pN2: Metastasis in four to nine axillary lymph nodes, or in clinically 
apparent internal mammary lymph nodes in the absence of axillary lymph 
node metastasis to ipsilateral axillary lymph node(s) fixed to each other 
or to other structures 
 
54
pN2a: Metastasis in four to nine axillary lymph nodes (at least one 
tumor deposit larger than 2.0 mm) 
pN2b: Metastasis in clinically apparent internal mammary lymph 
nodes in the absence of axillary lymph node metastasis 
pN3: Metastasis in 10 or more axillary lymph nodes, or in infraclavicular 
lymph nodes, or in clinically apparent ipsilateral internal mammary 
lymph node(s) in the presence of one or more positive axillary lymph 
node(s); or, in more than three axillary lymph nodes with clinically 
negative microscopic metastasis in internal mammary lymph nodes; or, in 
ipsilateral supraclavicular lymph nodes 
pN3a: Metastasis in ten or more axillary lymph nodes (at least one 
tumor deposit larger than 2.0 mm); or, metastasis to the 
infraclavicular lymph nodes 
pN3b: Metastasis in clinically apparent ipsilateral internal 
mammary lymph nodes in the presence of one or more positive 
axillary lymph node(s); or, in more than three axillary lymph nodes 
and in internal mammary lymph nodes with microscopic disease 
detected by sentinel lymph node dissection but not clinically 
apparent 
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pN3c: Metastasis in ipsilateral supraclavicular lymph nodes 
DISTANT METASTASIS (M) 
MX: Presence of distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
AJCC STAGE GROUPINGS  
Stage 0 Stage IIIA 
Tis, N0, M0 T0, N2, M0 
Stage I T1f, N2, M0 
T1, N0, M0 T2, N2, M0 
Stage IIA T3, N1, M0 
T0, N1, M0 T3, N2, M0 
T1, N1, M0 Stage IIIB 
T2, N0, M0 T4, N0, M0 
Stage IIB T4, N1, M0 
T2, N1, M0 T4, N2, M0 
T3, N0, M0 Stage IIIC 
Any T, N3, M0 
Stage IV 
Any T, Any N, M1 
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Locally Advanced Breast Cancer (Stage 3) 
 
MANCHESTER CLASSIFICATION : 
STAGE 1 
Tumor confined to breast tissue. Not fixed to the pectoralis major, 
not fixed to chest wall, no nodes in axilla, no metastasis. 
STAGE 2 
Tumor of any size with peau d orange, or infiltration of skin less 
than the size of the tumor, tumor not fixed to pectoralis major or chest 
wall. Axillary nodes are palpable and mobile, no metastasis. 
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STAGE 3 
 Involvement of skin or peau d orange more than the size of the 
tumor. Tumor fixed to pectoralis major, axillary nodes are fixed, or 
supraclavicular nodes are palpable, no metastasis. 
STAGE 4 
 Chest wall fixation, involvement of opposite breast and axilla, 
distant metastasis in bones and lungs. 
PROGNOSTIC FACTORS IN BREAST CARCINOMA : 
TUMOR FACTORS : 
Axillary nodal status 
Tumor size 
Histological / nuclear grade 
Lymphatic / vascular invasion 
Hormone receptor status 
DNA content (ploidy, phase fraction ) 
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Extensive intraductal component 
Growth factor indicators- EGFR, Erb B2 
Factors relating to tumor invasion – cathepsin d, collagenase 
activity 
Factors relating to growth rate – p53, S-phase fraction 
Factors relating to cell adhesion – Cd44 glycoprotein 
HOST FACTORS : 
Age 
Menopausal status 
Family history 
Previous breast cancer 
Immunosuppression 
Nutrition 
Prior chemotherapy 
Prior radiation therapy 
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PROGNOSTIC FACTORS : 
LYMPH NODAL METASTASIS – 
 The single most important prognostic indicator of  the breast 
cancer is the ipsilateral axillary nodal status, with 4 being the magic 
number, above which there is dramatic reduction of long term survival. 
 The overall prognosis is good for node negative disease, with 75% 
disease free 10 year survival provided the other prognostic factors are 
favourable, but the survival drops to 50% if less than 4 nodes are 
microscopically involved, and to 25% if greater than 4 nodes are positive. 
 As may be expected lymphatic and vascular invasion has also been 
shown to be a poor prognostic factor. 
 Nodal involvement in contralateral axilla is considered as distant 
metastatic disease and hence considered Manchester stage 4 and TNM 
stage 4. If this is the only finding upstaging the disease to stage 4, it has 
to be established beyond doubt, by either FNAC or excision biopsy. 
TUMOR SIZE – 
 Large tumors have a significantly worse prognosis, all the other 
factors obviously contribute to the metastatic potential of a given tumor. 
 
60
 The recurrence rate is significantly higher for a larger tumor, and 
the relapse free survival significantly lower. 
 From the excised specimen assessing the degree of invasive 
component of the breast is a better predictor of its biological behaviour 
than the total tumor size. 
HISTOLOGICAL GRADE- 
 It is based on Bloom and Richardson classification system. 
 Grade is classified as 1, 2, 3 based on tubule formation, nuclear 
pleomorphism, and mitotic rate. Mitotic rate is the most powerful factor. 
Grade 1- well differentiated 
Grade 2 – intermediate 
Grade 3 – poor differentiation 
TUMOR TYPE : 
 A pure mucinous or papillary type has a significantly better 
prognosis than a comedo carcinoma or NOS type. 
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CELL KINETICS AND PLOIDY : 
 The most significant predictor of  loco-regional relapse of 
carcinoma breast is cellular proliferation i.e, measuring the percentage of 
cells dividing at any given point of time and also the degree of cell 
division (which is shown by the nuclear grade). 
 Measurement of the rate of tumor cell division and the quantity of 
DNA (ploidy) in each cell helps to predict the course of node negative 
cancer. 
 The mitotic index (number of mitotic fiures/10HPF) has a 
predictive value for prognosis, with a distinctive advantage of it is <10 
figures. 
 The DNA index and the ‘S’ phase fraction measurement by flow 
cytometry are quick and reliable methods of quantifying the growth 
characteristics of the tumor and serve as good predictors of survival and 
recurrence. 
 The main impact of cell kinetic studies is in the clinical 
management of node negative breast cancer. 
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 The high ‘S’ phase fraction and aneuploidy are features that 
indicate a poor prognosis and adjuvant therapy would be strongly 
indicated in this group of patients even if node negative, as these tumors 
have a higher risk of locoregional recurrence. 
HORMONE RECEPTORS : 
 Identification of the oestrogen and the progesterone receptors (ER 
and PR) in the tumor cells by immunohistochemistry (IHC) is helpful in 
the prognosis and identifying the response to hormonal therapy. 
 When a high level of these receptors is found it often indicates the 
tumor is slow growing and the prognosis consequentially better, with 
90% probability of the tumor being responsive to hormonal manipulation. 
The reasons for better prognosis in ER / PR positive patients are : 
 They are generally well differentiated and slow growing tumors. 
 It is considered to be an index of cellular synthetic functions, 
influenced by alteration of hormonal milieu. 
 High probability of additional weapon against the tumor     
(hormonal therapy) being effective. 
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 Patients with tumors that are negative for both ER and PR have a 
slightly worse prognosis than those patients who have cancers with either 
ER or PR being positive. These data are based on NSABP-06 trial. 
Her 2- neu : 
 Human Epidermal Growth factor receptor 2 is a tyrosine kinase 
receptor, which plays a major role in normal cell growth. 
 Over expression of Her 2 neu (an oncogene) has been correlated 
with more aggressive cancer. Even in node negative women with over 
expression of Her 2, there is a strong correlation with early recurrence. 
 Though initial detection is done by IHC, gene amplification is to be 
verified by Florescence in situ hybridization technique (FISH), to exclude 
false positive reporting. 
 Targeted therapy using monoclonal antibody directed agaist Her 2 
neu receptor Trastuzumab (Herceptin) is used in these patients. 
Cathepsin – D : 
 Cathepsins are a family of enzymes that cleave the interior bond of 
various proteins. Normal breast tissue contains very little cathepsin d, but 
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high levels are found in breast cancer tissue. The higher the cathepsin d 
level, the shorter the disease free interval and overall survival. 
P53 : 
 Over expression of tumor suppressor gene p53 has been found to 
correlate with aggressive behaviour of tumor. This also affects radio and 
chemo sensitivity of the tumor, affecting the ultimate prognosis. 
THERAPEUTIC ROLE OF TAMOXIFEN : 
 About 90% of  ER / PR positive breast cancer and 10% of  ER / PR 
negative tumors are hormone dependent. Hence the rationale in offering 
hormone therapy is obvious. 
 Tamoxifen is an antagonist of the oestrogen receptor in breast 
tissue via its active metabolite,  hydroxytamoxifen. 
 In other tissues such as the endometrium, it behaves as an agonist, 
hence tamoxifen may be characterised as a mixed agonist / antagonist. 
 It has a half life of 5 – 7 days and has been standard endocrine 
(anti-oestrogen) therapy for hormone receptor positive breast cancer in 
Pre-menopausal women, while aromatase inhibitors are preferred for 
Post-menopausal women. 
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 Cells of some breast cancer require oestrogen to grow. Oestrogen 
binds to and activates ER in these cells. 
 Tamoxifen is metabolised into compounds that also bind to the ER, 
but do not activate it. Because of this competitive antagonism, tamoxifen 
acts like a key broken off  into a lock that prevents any other key from 
being inserted, preventing oestrogen from binding to its receptor. Hence 
breast cancer cell growth is blocked. 
 Tamoxifen is currently used for the treatment of  both early and 
advanced ER positive breast cancer in Pre and Post-menopausal women. 
Additionally it is most common hormonal agent used in the treatment of 
male breast cancer. It is also advocated for the prevention of breast cancer 
in high risk women e.g. against cancer in contralateral breast, though the 
concept has not gained wide popularity. 
 Other anti-oestrogen compounds in use: raloxifene and anastrazole 
are found to be equally effective against breast cancer, but with lesser risk 
of developing uterine cancers and thromboembolic complications. 
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THERAPEUTIC ROLE OF LETROZOLE : 
 Letrozole is an oral non steroidal aromatase inhibitor for the 
treatment of hormone responsive breast cancer after surgery in Post-
menopausal women. 
 Oestrogens are produced by the conversion of androgens by the 
activity of aromatase enzyme, which then binds to oestrogen receptors, 
stimulating cell division. 
 Letrozole prevents the aromatase from producing oestrogens by 
competitive reversible binding to the heme of its cytochrome p450 unit. 
This is action specific and do not interfere with the production of 
mineralocorticoids or glucocorticoids. 
 Letrozole is more effective in Post-menopausal women, in whom 
oestrogen is produced predominantly in the peripheral tissues (i.e. in 
adipose tissue and a number of sites in the brain) 
 Since in Pre-menopausal women the main source of oestrogen is 
from the ovaries and not the peripheral tissues, Letrozole is ineffective. 
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MATERIALS AND METHODS 
 This is a prospective study done in patients admitted in various 
wards in Rajiv Gandhi Government General Hospital,Chennai with signs 
and symptoms of carcinoma breast ,who were clinically evaluated and 
confirmed by FNAC / core-cut biopsy. 
Inclusion Criteria :  
 Patients presenting with signs and symptoms of carcinoma breast 
and diagnosed by FNAC / core-cut biopsy in various wards of Rajiv 
Gandhi Government General Hospital,Chennai. 
Exclusion Criteria :  
1] Patients with benign breast disorders 
2] Patients who refused any mode of therapy 
3] Patients who have been previously treated surgically for other breast     
ailments 
Sample Size : 50 patients 
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Investigation Details :  
 Detailed Clinical Examination, Routine Laboratory investigations, 
FNAC/core-cut biopsy, mammogram/USG-Breast, Chest X ray, USG-
Abdomen, Skeletal survey, HPE. 
EXAMINATION OF BREAST 
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OBSERVATION AND INFERENCE 
 A  total  number  of   50  cases of  breast  cancer  reported  in  
General  Surgery department  in  Rajiv  Gandhi  Government  General  
Hospital  Chennai  were taken  for  the  study.  Out  of  the  50  cases   
29  patients  were  pre-menopausal and  21  patients  were  post-
menopausal.
  
AGE  DISTRIBUTION : 
Age  in  years Number  of  patients 
21 – 30 1 
31 – 40 17 
41 – 50 13 
51 – 60 10 
61 – 70 7 
71 – 80 2 
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LATERALITY  OF  BREAST  CANCER 
 
 
 
CLINICAL STAGE AT PRESENTATION : 
 Among  Pre-menopausal  women  2  patients  presented  in  stage  
2B,  8  patients  presented  in  stage  3A,  12  patients  presented  in  Stage  
3B,  &  7  patients  presented  in stage  4. 
 Among  Post-menopausal  women  3  patients  presented  in  stage  
3A,  14  patients  presented  in  stage  3B,  &  4  patients  presented  in  
stage  4. 
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PRE-MENOPAUSAL WOMEN : 
 
POST-MENOPAUSAL WOMEN : 
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COMPARISION OF CLINICAL STAGE IN PRE-MENOPAUSAL 
AND POST-MENOPAUSAL WOMEN : 
 
 No  patients  in  both  Pre-menopausal  and  Post-menopausal  
group  presented  in  clinical  stage 1. 
 6.8%  of  patients  in  Pre-menopausal  group  and  none  of  the  
patients  in  Post-menopausal  group  presented  in  Stage 2. 
 68.96%  of  patients  in  Pre-menopausal  group  and  80.95%  of  
patients  in  Post-menopausal  group  presented  in  stage 3. 
 24.13%  of  patients  in  Pre-menopausal  group  and  19.04%  of  
patients  in  Post-menopausal  group  presented  in  stage 4. 
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COMPARISION  OF  BODY  MASS  INDEX  ( BMI ) : 
Classification  of  the  study  patients  according  to  BMI  is  done  as  per  
the  following  table, 
Classification BMI ( kg / m2) 
Underweight <18.5 
Normal Range 18.5 – 22.9 
Overweight 23 – 24.9 
Pre Obese 25 – 29.9 
Obese class 1 30 – 34.9 
Obese class 2 35 – 39.9 
Obese class 3 >40 
  
 Among  the  Pre-menopausal  patients  5  patients  were  
underweight,  17  patients  were  normal,  4  patients  were  overweight,  
and  3  patients  were  pre-obese  and  none  were  obese. 
 Among  the  Post-menopausal  patients  6  patients  were  
underweight,  10  patients  were  normal,  3  patients  were  overweight,  
1  patient  was  pre-obese  and  2  patients  were  obese  class-1. 
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PRE-MENOPAUSAL WOMEN : 
   
POST-MENOPAUSAL WOMEN : 
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COMPARISION OF BMI : 
 
17.24%  of  patients  in  Pre-menopausal  group  and  28.57%  of  
patients  in  Post-menopausal  group  were  Underweight. 
58.62%  of  patients  in  Pre-menopausal  group  and  47.61%  of  
patients  in  Post-menopausal  group  were  Normal. 
13.79%  of  patients  in  Pre-menopausal  group  and  14.28%  of  
patients  in  Post-menopausal  group  were  Over weight. 
10.34%  of  patients  in  Pre-menopausal  group  and  4.76%  of  
patients  in  Post-menopausal  group  were  Pre-obese. 
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 None  of  the  patients  in  Pre-menopausal  group  and  9.52%  of  
patients  in  Post-menopausal  group  were  Obese Class 1. 
 None  of  the  patients  in  Pre-menopausal  or  Post-menopausal  
groups  were  Obese Class 2 or 3.   
 
 
PATHOLOGICAL TYPES : 
 Among   29  Pre-menopausal  women,  24  patients  had  
infiltrating  ductal  carcinoma – NOS,  4  patients  had  lobular  
carcinoma  and  1  patient  had  cribriform  carcinoma. 
 Among  21  Post-menopausal  women,  15  patients  had  
infiltrating  ductal  carcinoma – NOS,  3  patients  had  lobular  
carcinoma,  2  patients  had  medullary  carcinoma  and  1  patient  had  
papillary  carcinoma. 
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PRE-MENOPAUSAL WOMEN : 
 
POST-MENOPAUSAL WOMEN : 
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COMPARISION OF HISTOPATHOLOGICAL TYPES IN PRE-
MENOPAUSAL AND POST-MENOPAUSAL WOMEN : 
 
82.75%  of  Pre-menopausal  women  and   71.42%  of  Post-
menopausal  women  had  histopathological  type  of  infiltrating  ductal  
carcinoma – NOS. 
13.79%  of  Pre-menopausal  women  and  14.28%  of  Post-
menopausal  women  had  histopathological  type  of  lobular  carcinoma. 
None  of  Pre-menopausal  women  and  9.5%  of  Post-menopausal  
women  had  histopathological  type  of  medullary  carcinoma. 
Other  histopathological  types  accounted  for  3.44%  in  Pre-
menopausal  women  and  4.76%  in  Post-menopausal  women. 
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ER / PR STATUS : 
 Among  Pre-menopausal women  18  patients  are  ER / PR  
positive  and  11  patients  are  ER / PR  negative. 
 Among  Post-menopausal  women  17  patients  are  ER / PR  
positive  and  4  patients  are  ER / PR  negative.   
 
62.06%  of  Pre-menopausal  women  and  80.95%  of  Post-
menopausal  women  are  ER / PR  positive. 
37.93%  of  Pre-menopausal  women  and  19.04%  of  Post-
menopausal  women  are  ER / PR  negative. 
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ASSOCIATED  PROLIFERATIVE  BREAST  DISEASE : 
 Among   the  29  Pre-menopausal  patients  7  patients  had  
associated  proliferative  breast  disease. 
 Among  the  21  Post-menopausal  patients  3  patients  had  
associated  proliferative  breast  disease. 
PROLIFERATIVE  BREAST  DISEASE : 
 
24.13%  of  Pre-menopausal  patients  had  associated  proliferative  
breast  disease. 
14,28%  of  Post-menopausal  patients  had  associated  
proliferative  breast  disease. 
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MAMMOGRAPHIC ABNORMALITIES IN CONTRALATERAL 
BREAST : 
 Among  29  Pre-menopausal  patients  3  patients  had  
mammographic  abnormalities  in  the  contralateral  breast  out  of  which  
2  were  BIRADS 3  and  1  was  BIRADS 5. 
 Among  21  Post-menopausal  patients  1  patients  had  
mammographic  abnormality  in  the  contralateral  breast  which  was  
BIRADS 3. 
   
10.34%  of  Pre-menopausal  women  and  4.76%  of  Post-
menopausal  women  had  mammographic  abnormalities  in  contralateral  
breast. 
 The  overall  percentage  of  contralateral  mammographic  
abnormality  was  8%  taking  into  account  both  Pre-menopausal  and  
Post-menopausal  groups. 
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DISCUSSION 
 This  study  aims  at  comparing  various  parameters  in  
carcinoma  breast  in  Pre-menopausal  and  Post-menopausal  women  
and  inferring  the  compared  parameters  among  50  patients  in  our  
General  Surgery  department. 
 In  my  study  comprising  50  patients,  29  patients  were  Pre-
menopausal  and  21  patients  were  Post-menopausal. 
 As   the  Clinical  stage  at  presentation  to  the  surgical  
department  increases,  the  5 year  overall  and  disease  free  survival  
decreases.  Majority  of  patients  in  Pre-menopausal  group  and  all  the  
patients  in  Post-menopausal  group  presented  in  stage 3 (Locally 
Advanced Breast Cancer)  and  stage 4 (Metastatic Breast cancer).  On  
comparing  both  the  groups  the  proportion  of  patients  presenting  in  
advanced  stage  3 or 4 is  higher  in  Post-menopausal  group  than  Pre-
menopausal  group. 
 Obesity  is  a  significant  risk  factor  for  the  development  of  
Post-menopausal  breast  cancer  possibly  due  to  production  of  
oestrogen  from  extra gonadal  sites  particularly  adipose  tissue.  
Obesity  is  also  a  protective  factor  against  the  development  of  breast  
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cancer  in  Pre-menopausal  women  possibly  as  a  result  of  decreased  
exposure  to  oestrogen  which  in  turn  is  due  to  increased  number  of  
irregular  menstrual  cycles.  Increase  in  BMI    (Body Mass Index)  is  
directly  proportional  to  increased  risk  of  developing  breast  
carcinoma.  There  is  a  4%  increase  in  odds  of  Post-menopausal  
breast  cancer  for  every  1 kg/m2  increase  in  BMI.   
 BMI > 31.1  has 2.5 fold increased risk. Taking  31.1  as  cut  off  
value, none  of  the  women  in  Pre-menopausal  group  and  2  women  
in  the  post-menopausal  group  were  above  the  cut  off  value.  The  
proportion  of  patients  with  obesity  is  higher  in  the  Post-menopausal  
group. 
 Histopathological  type  of  carcinoma  breast  also  carries  
prognostic  significance  with  Invasive  ductal  carcinoma – NOS  having   
a  poor  prognosis  compared  to  Invasive  lobular  carcinoma  and  all  
other  special  types  of  cancer  breast (medullary, papillary, cribriform 
etc.).  In  my  study  Infiltrating  ductal  carcinoma – NOS  was  the  most  
common  histopathological  type  of  breast  cancer  in  both  Pre-
menopausal  and  Post-menopausal  groups,  but  the  proportion  of  
Invasive  lobular  carcinoma  and  other  special  histopathological  types  
of  breast  cancer  was  higher  in  Post-menopausal  women. 
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 ER / PR  positivity  is  present  in  70%  of  patients  with  breast  
cancer.  ER / PR  positivity  is  more  common  in  older  Post-
menopausal  women.  Oestrogen  deprivation  therapy  using  tamoxifen / 
aromatase inhibitors  are  more  effective  in  older  Post-menopausal  
women  than  younger Pre-menopausal  women  due  to  the  absence  of  
oestrogen  produced  from  the  ovaries.  In  my  study  the  proportion  of  
ER / PR  positivity  is  higher  in  Post-menopausal  women  compared  to  
Pre-menopausal  women. 
 Women  with  proliferative  breast  disease  have  approximately  
twice  the  risk  of  developing  carcinoma  breast,  regardless  of   
menopausal  status,  when  compared  with  women  from  general  
population.  Proliferative  disease  of  breast  are  more  common  in  Pre-
menopausal  women.  Post-menopausal  women  with  senile  involution  
of  breast  lacking  proliferative  activity  have  decreased  risk  for  the  
development  of  breast  cancer.  In  my  study  the  proportion  of  
patients  with  proliferative  breast  disease  was  higher  in  Pre-
menopausal  group  compared  to  Post-menopausal  group. 
 The proportion of contralateral in situ disease has increased from 
5% to 33% with the use of mammography.  In my study the proportion  
of  patients  with  contralateral  mammographic  abnormality  was  higher  
in  Pre-menopausal  group  compared  to  Post-menopausal  group  and  
the  overall  incidence  was  8%. 
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CONCLUSIONS 
 1. Majority  of  women  in  both  Pre-menopausal  and  Post-
menopausal  groups  presented  at  an  advanced  clinical  stage ( stages 3 
and 4),  the  proportion  of  Post-menopausal  women  higher  than  the  
Pre-menopausal  women. 
 2. Incidence  of  obesity  is  higher  in  Post-menopausal  
women  with  breast  cancer  signifying  positive  correlation  between  
Post-menopausal  obesity  and  development  of  breast  cancer. 
 3. Infiltrative  ducal  carcinoma – NOS  was  the  most  
common  histopathological  type  of  breast  cancer  in  both  the  groups.  
But  the  proportion  of  Invasive  lobular  carcinoma  and  other  special  
types  of  carcinoma  breast  having  better  prognosis  is  common  
among  Post-menopausal  women. 
 4. The  proportion  of  ER /PR  positivity  is  higher  among  
Post-menopausal  women  and  hence  a  better  prognosis,  as  these  
patients  are  capable  of  hormonal  manipulation  using  adjuvant  
endocrine  therapy. 
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 5. The  proportion  of  associated  proliferative  breast  disease  
was  higher  in  Pre-menopausal  patients,  hence  they  are  at  increased  
risk  of  developing  contralateral  breast  cancer  in  future. 
 6. The overall  incidence  of  contralateral  mammographic  
abnormality  was  8%  and  the  proportion  is  higher  in  Pre-menopausal  
women compared  to  Post-menopausal  women. 
PROFORMA 
Name 
Age / sex 
Weight, Height & BMI 
Occupation 
Chief complaints- 
History of presenting illness- 
Presence of lump 
Which side ? 
Site, Duration 
Change in size of the lump- gradual or sudden 
Any pain or fever associated 
Trauma 
Discharge from nipple 
Skin changes 
Lump in axilla 
Arm oedema 
Bony pain, history of  jaundice, history of breathlessness 
PAST HISTORY 
Previous benign breast lump excision 
Irradiation to breast 
MENSTRUAL HISTORY 
Date of menarche 
Date of menopause 
Last menstrual period 
Cycles regular / irregular 
Amenorrhoea, menorrhagia, dysmenorrhoea 
OBSTETRIC HISTORY 
Age at first child birth 
Number of children 
Breast feeding and duration 
Use of oral contraceptive pills 
Consanguineous or non-consanguineous marriage 
PERSONAL HISTORY 
Loss of weight  
Loss of appetite 
Loss of sleep 
Bowel and bladder habits 
FAMILY HISTORY 
Similar history in the family 
CLINICAL EXAMINATION 
GENERAL EXAMINATION 
Pallor, icterus, lymphadenopathy, pedal oedema 
Pulse rate 
Blood pressure 
Respiratory rate  
Temperature 
Skull and spine and ends of  long bones 
Per abdomen 
Ascites 
Hepatomegaly 
Krukenberg tumor 
Cardio vascular system- Heart sounds 
Respiratory – Breath sounds and altered sounds, pleural effusion 
 
INSPECTION 
Patient in sitting position arms by the side 
Both breasts look symmetrical / asymmetrical 
Both nipple at same level or not 
Retraction of the nipple 
Discharge from nipple 
Ulceration over nipple areola complex 
Peau d’orange over the areola 
Dimpling or puckering 
Any fullness or lump seen in any quadrant 
Site, size shape, surface, all margins well defined or not 
 
Arms above the head 
Inframammary fold 
Nipple retraction 
Puckering or dimpling of skin 
On bending forward 
If both breasts falling forward equally 
Opposite breast, opposite axilla, oedema of the arm 
PALPATION 
Normal breast is palpated first 
Diseased breast- 
Warmth, tenderness, site, size, shape, surface, consistency and borders of 
the lump 
Skin pinchability 
On putting the pectoralis major into contraction- 
Move the lump along the fibres and then across the fibres 
Moving with the breast tissue or independent of the breast tissue 
Axillary nodes are palpated – anterior, posterior, central and apical 
groups 
Site, size, number of nodes palpable, consistency, tenderness, fixed or 
discrete. 
PERCUSSION 
Internal mammary nodes in 2nd, 3rd and 4th intercostal spaces 
OTHER SYSTEMS 
CLINICAL  
STAGING 
INVESTIGATIONS 
Fine needle aspiration cytology 
Mammography 
Chest x ray 
Ultrasound abdomen 
SURGERY 
Modified radical mastectomy 
HISTOPATHOLOGY 
ER, PR STATUS by immune-histochemistry 
the breast, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 
2004. 
 
18. The World Health Organization histological typing of breast 
tumors, 2nd ed. The World Organization. Am J Clin Pathol 1982. 
 
19. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer 
screening: a summary of the evidence for the U.S. Preventive 
Services Task Force. Ann Intern Med 2002. 
 
20. Schnitt SJ. Estrogen receptor testing of breast cancer in current 
clinical practice: what's the question? J Clin Oncol 2006. 
 
21. Chang J, Hilsenbeck SG. Prognostic and predictive markers. In: 
Harris LM Jr, Morrow M, Osborne CK, eds. Diseases of the breast, 
3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004. 
 
22. IBCSG. Endocrine responsiveness and tailoring adjuvant therapy 
for postmenopausal lymph node-negative breast cancer: a 
randomized trial. J Natl Cancer Inst 2002. 
 
23. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N 
Engl J Med 2003. 
 
24. Howell A, Cuzick J, Baum M, et al. Results of the ATAC 
(Arimidex, Tamoxifen, Alone or in Combination) trial after 
completion of 5 years' adjuvant treatment for breast cancer. Lancet 
2005. 
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Vijayalakshmi 38 F Pre-menopausal Right 113932 3A 21.4 Ductal-NOS Positive Positive 1
Latha 32 F Pre-menopausal Right 113904 3B 18.2 Ductal-NOS Negative Negative 1
Munikannamma 61 F Post-menopausal Left 103185 3B 19.2 Medullary Positive Negative 1
Kala 62 F Post-menopausal Left 96601 4 18.3 Ductal-NOS Negative Negative 1
Pitchaiammal 48 F Pre-menopausal Right 96522 3B 18.7 Ductal-NOS Negative Negative 1
Usha 35 F Pre-menopausal Right 84088 3B 18.5 Ductal-NOS Positive Negative 1
Radha bai 80 F Post-menopausal Right 81691 3B 19 Ductal-NOS Positive Negative 1
Padma 40 F Pre-menopausal Right 81711 3A 24.1 Lobular Positive Negative 1
Govindammal 40 F Pre-menopausal Right 99291 3B 26.3 Ductal-NOS Negative Positive 1
Savithri 45 F Pre-menopausal Left 68924 4 21.3 Ductal-NOS Positive Positive 3
NAME AGE SEX MENOPAUSAL STATUS LATERALITYIP NO CLINICAL STAG BMI HPE ER / PR PROLIFERATIVE DISEASEBIRADS
Aisha bee 75 F Post-menopausal Right 67655 3B 18.9 Ductal-NOS Positive Negative 1
Kamala 55 F Post-menopausal Left 64310 3B 18.8 Lobular Positive Negative 1
Nagamani 45 F Pre-menopausal Right 61831 4 18.4 Ductal-NOS Negative Negative 1
Krishnaveni 50 F Post-menopausal Right 57336 3A 19.8 Ductal-NOS Negative Positive 1
Kuppammal 47 F Post-menopausal Left 54906 3B 19.7 Ductal-NOS Positive Negative 1
Parameshwari 40 F Pre-menopausal Left 25464 3B 23.2 Lobular Positive Negative 1
Parvathy 65 F Post-menopausal Left 27726 3A 19.4 Ductal-NOS Positive Negative 1
Lakshmi 58 F Post-menopausal Right 31754 3B 32.4 Ductal-NOS Positive Negative 1
Pappammal 62 F Post-menopausal Right 40690 3B 18.3 Ductal-NOS Positive Negative 1
Latha 42 F Pre-menopausal Left 43106 3B 28.5 Ductal-NOS Positive Negative 3
Dhanalakshmi 35 F Pre-menopausal Right 94312 2B 27.2 Ductal-NOS Positive Negative 1
Jamuna 55 F Post-menopausal Left 99566 3B 24.9 Ductal-NOS Positive Negative 1
Saroja 50 F Pre-menopausal Right 97088 4 24 Lobular Positive Negative 1
Kavitha 44 F Pre-menopausal Right 84181 3A 20.3 Ductal-NOS Positive Negative 1
Govindammal 30 F Pre-menopausal Right 86074 2B 20.7 Ductal-NOS Negative Negative 1
Poongodi 44 F Pre-menopausal Right 86877 3B 18.4 Ductal-NOS Positive Negative 1
Saraswathi 54 F Post-menopausal Right 74883 4 23.2 Lobular Negative Negative 1
Sengammal 52 F Post-menopausal Left 74844 3B 18.4 Ductal-NOS Negative Positive 1
Padma 31 F Pre-menopausal Right 74233 4 21.9 Ductal-NOS Positive Negative 1
Ahila 40 F Pre-menopausal Right 76952 4 20.5 Ductal-NOS Negative Negative 1
Kumari 55 F Post-menopausal Left 77436 3B 24.3 Medullary Positive Negative 1
Kondamma 39 F Pre-menopausal Left 79771 3A 18.6 Ductal-NOS Positive Negative 1
Natchiyammal 35 F Pre-menopausal Right 80036 3A 18.3 Ductal-NOS Positive Positive 1
Vijayalakshmi 35 F Pre-menopausal Left 77475 3B 18.4 Lobular Positive Negative 1
Jeyanthi 44 F Pre-menopausal Left 80602 3B 19.3 Ductal-NOS Negative Negative 1
Rajeshwari 68 F Post-menopausal Right 81691 4 19.1 Papillary Positive Positive 1
Padmavathi 48 F Pre-menopausal Left 81761 3B 18.1 Ductal-NOS Positive Negative 1
Lakshmi 54 F Post-menopausal Right 80252 3A 21.3 Ductal-NOS Positive Negative 1
Andal 58 F Post-menopausal Left 78897 3B 27.8 Ductal-NOS Positive Negative 1
Visalakshi 65 F Post-menopausal Right 81627 3B 18.7 Ductal-NOS Positive Negative 1
Varagu 50 F Pre-menopausal Left 77062 3A 23.5 Ductal-NOS Negative Negative 1
Logeshwari 40 F Pre-menopausal Bilateral 77644 4 20.9 Ductal-NOS Negative Positive 5
Neela 39 F Pre-menopausal Right 81987 3B 22.3 Ductal-NOS Positive Negative 1
Sarala 55 F Post-menopausal Left 81904 3B 31.3 Ductal-NOS Positive Negative 1
Raniyammal 72 F Post-menopausal Right 82000 4 19.6 Ductal-NOS Positive Negative 1
Lakshmi 32 F Pre-menopausal Left 62156 3A 19.4 Lobular Negative Negative 1
Ambika 60 F Post-menopausal Right 61518 3B 18.4 Ductal-NOS Positive Negative 3
Jeyanthi 42 F Pre-menopausal Left 59988 3A 21.1 Ductal-NOS Positive Positive 1
Pushpa 39 F Pre-menopausal Right 58168 4 18.4 Cribriform Positive Positive 1
Farzana 42 F Pre-menopausal Left 57186 3B 18.6 Ductal-NOS Negative Negative 1
